192 related articles for article (PubMed ID: 26986210)
1. Critical reanalysis of the methods that discriminate the activity of CDK2 from CDK1.
Sakurikar N; Eastman A
Cell Cycle; 2016 May; 15(9):1184-8. PubMed ID: 26986210
[TBL] [Abstract][Full Text] [Related]
2. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
[TBL] [Abstract][Full Text] [Related]
3. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
Sakurikar N; Thompson R; Montano R; Eastman A
Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
[TBL] [Abstract][Full Text] [Related]
4. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
Wood DJ; Korolchuk S; Tatum NJ; Wang LZ; Endicott JA; Noble MEM; Martin MP
Cell Chem Biol; 2019 Jan; 26(1):121-130.e5. PubMed ID: 30472117
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
6. Dual regulation of the anaphase promoting complex in human cells by cyclin A-Cdk2 and cyclin A-Cdk1 complexes.
Mitra J; Enders GH; Azizkhan-Clifford J; Lengel KL
Cell Cycle; 2006 Mar; 5(6):661-6. PubMed ID: 16582612
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
Coppock DL; Buffolino P; Kopman C; Nathanson L
Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.
Johnson N; Bentley J; Wang LZ; Newell DR; Robson CN; Shapiro GI; Curtin NJ
Br J Cancer; 2010 Jan; 102(2):342-50. PubMed ID: 20010939
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of mixed lineage kinase MLK3 by cyclin-dependent kinases CDK1 and CDK2 controls ovarian cancer cell division.
Cedeno-Rosario L; Honda D; Sunderland AM; Lewandowski MD; Taylor WR; Chadee DN
J Biol Chem; 2022 Aug; 298(8):102263. PubMed ID: 35843311
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of 6-(het) ary Xylocydine analogues and evaluating their inhibitory activities of CDK1 and CDK2 in vitro.
Xiao C; Sun C; Han W; Pan F; Dan Z; Li Y; Song ZG; Jin YH
Bioorg Med Chem; 2011 Dec; 19(23):7100-10. PubMed ID: 22036212
[TBL] [Abstract][Full Text] [Related]
11. S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells.
Hu B; Mitra J; van den Heuvel S; Enders GH
Mol Cell Biol; 2001 Apr; 21(8):2755-66. PubMed ID: 11283255
[TBL] [Abstract][Full Text] [Related]
12. Unmasking the redundancy between Cdk1 and Cdk2 at G2 phase in human cancer cell lines.
L'Italien L; Tanudji M; Russell L; Schebye XM
Cell Cycle; 2006 May; 5(9):984-93. PubMed ID: 16687918
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of CDP/Cux p110 by cyclin A/Cdk2 and cyclin A/Cdk1.
Santaguida M; Nepveu A
J Biol Chem; 2005 Sep; 280(38):32712-21. PubMed ID: 16081423
[TBL] [Abstract][Full Text] [Related]
14. Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle.
Oakes V; Wang W; Harrington B; Lee WJ; Beamish H; Chia KM; Pinder A; Goto H; Inagaki M; Pavey S; Gabrielli B
Cell Cycle; 2014; 13(20):3302-11. PubMed ID: 25485510
[TBL] [Abstract][Full Text] [Related]
15. Cyclin A/Cdk2 complexes regulate activation of Cdk1 and Cdc25 phosphatases in human cells.
Mitra J; Enders GH
Oncogene; 2004 Apr; 23(19):3361-7. PubMed ID: 14767478
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Cdk2 activation by selected tyrphostins causes cell cycle arrest at late G1 and S phase.
Kleinberger-Doron N; Shelah N; Capone R; Gazit A; Levitzki A
Exp Cell Res; 1998 Jun; 241(2):340-51. PubMed ID: 9637776
[TBL] [Abstract][Full Text] [Related]
17. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.
Cai D; Byth KF; Shapiro GI
Cancer Res; 2006 Jan; 66(1):435-44. PubMed ID: 16397259
[TBL] [Abstract][Full Text] [Related]
18. Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity.
Guadagno TM; Newport JW
Cell; 1996 Jan; 84(1):73-82. PubMed ID: 8548828
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
Mou J; Chen D; Deng Y
Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
[TBL] [Abstract][Full Text] [Related]
20. Yeast as a model system to screen purine derivatives against human CDK1 and CDK2 kinases.
Mayi T; Facca C; Anne S; Vernis L; Huang ME; Legraverend M; Faye G
J Biotechnol; 2015 Feb; 195():30-6. PubMed ID: 25541464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
